Clinical Trial Update: HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.

View source ↗

Summary

Expanded access program HBCMD01 for congenital muscular dystrophy due to LMNA mutation is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Muscular Dystrophy Due to Lmna Mutation

Drugs mentioned

• HBCMD01

Snippet

Sponsor: Hope Biosciences Research Foundation | Conditions: Congenital Muscular Dystrophy Due to Lamin A/C Mutation | Status: NO_LONGER_AVAILABLE